Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

22P - Clinical significance of DNA damage response mutations in early stage NSCLC

Date

21 Oct 2023

Session

Poster session 09

Topics

Basic Science;  Cancer in Special Situations/ Populations;  Cancer Research

Tumour Site

Non-Small Cell Lung Cancer;  Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Haoran Zhang

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

H. Zhang

Author affiliations

  • Department Of Respiratory And Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking - Dongcheng/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 22P

Background

DNA damage response (DDR) pathways are essential to sustain genomic stability and play a critical role in cancer development and progression. Here, we investigated DDR genes mutations profile in early-stage non-small cell lung cancer (NSCLC) and their prognostic values.

Methods

We first examined 74 DDR genes involved in seven DDR pathways and then focused on six specific genes: ATM, BRCA1/2, CHEK1, BARD1, BRIP1. A total of 179 stage I and IIIa NSCLC patients who received curative resection in Peking Union Medical College Hospital and their corresponding samples were collected for DNA sequencing, immunohistochemistry and survival analysis.

Results

A total of 167 eligible patients were finally analyzed. Mutation frequencies were 82% and 26.3% for the selected 74 genes and 6 genes, respectively. No association was found between DDR gene status and PD-L1 expression, CD8 positive lymphocyte and tumor-associated macrophage (TAM) infiltration in tumor area. Numbers of gene mutations was significantly increased among patients with DDR alterations. Deleterious mutations in ATM, BRCA1/2, CHEK1, BARD1 and BRIP1 were independent prognostic indicators of significantly longer disease-free survival.

Conclusions

Deleterious mutations of these six genes were common in early-stage NSCLC and may serve as prognostic biomarkers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

National High Level Hospital Clinical Research Funding (to MW), Grant/Award Number:2022-PUMCH-B-106.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.